Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.01 (1y: +3%)
Market Cap 180.9 M P/E(ttm)
Enterprise Value 152.89 M P/B 6.70
NEPT- NAS (USA)
Neptune Technologies & Bioressources Inc.
Not Rated
Top Ranked Predictable Companies
$3.01
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 2.864
NEPT's Cash to Debt is ranked lower than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NEPT: 2.864 )
NEPT' s 10-Year Cash to Debt Range
Min: 0.05   Max: 2.86
Current: 2.86
0.05
2.86
Equity to Asset 0.59
NEPT's Equity to Asset is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. NEPT: 0.59 )
NEPT' s 10-Year Equity to Asset Range
Min: -0.44   Max: 0.59
Current: 0.59
-0.44
0.59
F-Score: 3
Z-Score: 5.39
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -29.90
NEPT's Operating margin (%) is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. NEPT: -29.90 )
NEPT' s 10-Year Operating margin (%) Range
Min: -116.2   Max: -11
Current: -29.9
-116.2
-11
Net-margin (%) -24
NEPT's Net-margin (%) is ranked lower than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. NEPT: -24 )
NEPT' s 10-Year Net-margin (%) Range
Min: -156.2   Max: 3.1
Current: -24
-156.2
3.1
ROE (%) -16.5
NEPT's ROE (%) is ranked lower than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. NEPT: -16.5 )
NEPT' s 10-Year ROE (%) Range
Min: -59.1   Max: 3.6
Current: -16.5
-59.1
3.6
ROA (%) -10.3
NEPT's ROA (%) is ranked lower than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. NEPT: -10.3 )
NEPT' s 10-Year ROA (%) Range
Min: -44.6   Max: 2.2
Current: -10.3
-44.6
2.2
ROC (Joel Greenblatt) (%) -31.30
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. NEPT: -31.30 )
NEPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.4   Max: -12.4
Current: -31.3
-50.4
-12.4
Revenue Growth (%) 9.3
NEPT's Revenue Growth (%) is ranked higher than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NEPT: 9.3 )
NEPT' s 10-Year Revenue Growth (%) Range
Min: 8.8   Max: 23.1
Current: 9.3
8.8
23.1
EPS Growth (%) -25.5
NEPT's EPS Growth (%) is ranked higher than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. NEPT: -25.5 )
NEPT' s 10-Year EPS Growth (%) Range
Min: -25.5   Max: 17.2
Current: -25.5
-25.5
17.2
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NEPT Guru Trades in

NEPT Guru Trades in

Q3 2012

NEPT Guru Trades in Q3 2012

Steven Cohen 12,967 sh (New)
» More
Q4 2012

NEPT Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NEPT



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 6.70
NEPT's P/B is ranked higher than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NEPT: 6.70 )
NEPT' s 10-Year P/B Range
Min: 1.91   Max: 40.88
Current: 6.7
1.91
40.88
P/S 5.90
NEPT's P/S is ranked higher than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. NEPT: 5.90 )
NEPT' s 10-Year P/S Range
Min: 0.87   Max: 34.78
Current: 5.9
0.87
34.78
PFCF 99.20
NEPT's PFCF is ranked higher than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. NEPT: 99.20 )
NEPT' s 10-Year PFCF Range
Min: 20   Max: 126
Current: 99.2
20
126
EV-to-EBIT 500
NEPT's EV-to-EBIT is ranked lower than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. NEPT: 500 )
NEPT' s 10-Year EV-to-EBIT Range
Min: 339.9   Max: 579.2
Current: 500
339.9
579.2

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 16.5
NEPT's Price/Net Current Asset Value is ranked higher than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. NEPT: 16.5 )
NEPT' s 10-Year Price/Net Current Asset Value Range
Min: 5.5   Max: 75.2
Current: 16.5
5.5
75.2
Price/Tangible Book 6.9
NEPT's Price/Tangible Book is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. NEPT: 6.9 )
NEPT' s 10-Year Price/Tangible Book Range
Min: 5.6   Max: 35.6
Current: 6.9
5.6
35.6
Price/Median PS Value 0.9
NEPT's Price/Median PS Value is ranked higher than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. NEPT: 0.9 )
NEPT' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 4.6
Current: 0.9
0.2
4.6
Earnings Yield (Greenblatt) 0.20
NEPT's Earnings Yield (Greenblatt) is ranked higher than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. NEPT: 0.20 )
NEPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 0.3
Current: 0.2
0.2
0.3
Forward Rate of Return (Yacktman) -2.42
NEPT's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. NEPT: -2.42 )
NEPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.4   Max: -1.9
Current: -2.42
-3.4
-1.9

Business Description

Neptune Technologies & Bioressources Inc. was incorporated on October 9, 1998. Neptune is a biotechnology company involved in the research and development of novel extraction technologies, potent biological therapeutics agents, intellectual property and development of products for highly prevalent chronic conditions, namely cardiovascular and neurodegenerative diseases. The main focus of the Company is to identify marine biomasses pure from toxins, abundant and underexploited; to research, develop and commercialize novel technology for the extraction and stabilization of potent marine biological therapeutic agents; and to research and develop the safety and therapeutic efficacy of compounds for highly prevalent atherosclerotic conditions like cardiovascular diseases as well as for neurodegenerative and inflammation related conditions. Neptune manufactures its products at its Sherbrooke plant and sells NKO in bulk oil or in capsules to its distributors who commercialize under their private label in multiple market segments including health food stores, mass (food and drug), direct sales (MLM, internet, catalogue, radio) and via healthcare professional recommendation. The Company is subject to federal, provincial, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products.
Company Website
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:NTB.Canada

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial